Kintor's GT20029 Topical for Androgenetic Alopecia

[jondoeuk]

GT20029 is an androgen receptor degrader (AR Degrader). It was developed using a proprietary Proteolysis Targeting Chimera (PROTAC) platform. This is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter clinical trials. GT20029 degrades the AR protein via the E3 ubiquitin ligase pathway. https://en.wikipedia.org/wiki/Ubiquitin_ligase#Targeted_protein_degradation

In 2024, Kintor Pharma announced that its phase two clinical trial had reached the primary endpoint. The results were statistically significant and clinically meaningful. https://en.kintor.com.cn/news_details/1803365125008502784.html

GT20029 demonstrated statistically significant efficacy compared to placebo in both the QD (once a day) and BIW (twice a week) dosing cohorts. After 12 weeks of treatment, the 0.5% QD GT20029 group showed an increase of 16.80 hairs/cm² from baseline. This was 6.69 hairs/cm² more than the placebo group. The total area hair count (TAHC) of GT20029 1.0% BIW group showed an increase of 11.94 hairs/cm² from baseline. This was 7.36 hairs/cm² more than the placebo. The 1% BIW dosage of GT20029 was identified as the optimal dosing level.

 

[jondoeuk]

The randomised, double-blind, placebo-controlled phase two clinical trial was published. It entailed 180 Chinese adult males with androgenetic alopecia (Hamilton-Norwood IIIv-V). It lasted from April 2023 to April 2024. The subjects were randomised equally into six groups receiving GT20029 (0.5% or 1.0%) or placebo, either once daily (QD) or twice weekly (BIW) for 12 weeks. All four GT20029-treated groups showed significant increases in target area hair count (TAHC) at Week 12. Target area hair width (TAHW) also improved significantly in the 1.0% BIW group vs placebo. https://www.tandfonline.com/doi/10.1080/09546634.2025.2574304

 

[jondoeuk]

Kintor plans to initiate the phase IIb/III clinical trial of GT20029 for male androgenetic alopecia in China this year.